Role of Siddha medicine in the management of Covid-19 positive patients

â??An Open Clinical Trial to Evaluate the Safety & Efficacy of Siddha Sastric Medicines â?? Fixed Regimen in COVID-19 Positive asymptomatic, mild or moderate cases with reference to the Siddha guidelines of COVID-19 management, Ministry of AYUSH, Govt. of India at TPEC COVID-19 CARE Centre , Vellore ,Tamilnaduâ??

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027397

Enrollment

Registered

2020-08-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: KAPA SURA KUDINEER: 60 ML TWICE DAILY for one week Intervention2: AMUKKARA CHOORANAM TABLET: 2 TABLET THRICE DAILY for one week Intervention3: THALISATHY VADAGAM: 2 TABLET THRICE DAILY

Eligibility

Inclusion criteria

Inclusion criteria: S.No Parameter 1. Adult Male/Female subjects above the age of 18 years 2. COVID -19 Positive as determined by RT-PCR 3. Willing to provide written/digital informed consent. 4. COVID - 19 Positive with no clinical signs 5. COVID - 19 Positive with mild symptoms â?? Sneezing, Cough, Sore Throat, Throat Pain, Malaise, Tiredness, Fever, loss of smell, loss of taste 6. COVID - 19 Positive with moderate symptoms â?? Fever with cough, breathlessness but respiratory rate 95% at rest

Exclusion criteria

Exclusion criteria: S. No Parameter 1. Pregnant and Lactating females 2. COVID - 19 Positive with Severe symptoms â?? Respiratory distress ( >24 breath per minute), Oxygen saturation 3. Chronic Renal Failure requiring dialysis (eGFR 4. Known cases of uncontrolled Diabetes ( >9% HbA1c) 5. Known cases of stage 3 Hypertension ( > 160/100 mmHg) 6. Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening 7. Subjects having immune compromised status like HIV, Hepatitis, Tuberculosis, Cancer etc. 8. Subjects taking Steroid treatment and or any kind of immunosuppressive therapy 9. Subjects who are participating in any other clinical study or having participated in any other study 1 month prior to screening in the present study. 10. Subjects with bleeding disorders and severe anemia (Hb

Design outcomes

Primary

Measure	Time frame
â?¢ Reduction in Viral load of SARS-CoV-2 at the end of treatment â?¢ Reduction in clinical symptoms like fever, cough and breathlessness (1. Fever: â?¤36.6Â°C or -axilla, â?¤37.2 Â°C oral or â?¤37.8Â°C rectal or tympanic ; (2. Respiratory rate - â?¤24/minute on room air; (3. Cough - mild or absent on a patient reported scale (cough symptoms score â?¤ 2 points) Timepoint: ONE WEEK	—

Measure

Time frame

â?¢ Reduction in Viral load of SARS-CoV-2 at the end of treatment â?¢ Reduction in clinical symptoms like fever, cough and breathlessness (1. Fever: â?¤36.6Â°C or -axilla, â?¤37.2 Â°C oral or â?¤37.8Â°C rectal or tympanic ; (2. Respiratory rate - â?¤24/minute on room air; (3. Cough - mild or absent on a patient reported scale (cough symptoms score â?¤ 2 points) Timepoint: ONE WEEK

—

Secondary

Measure	Time frame
â?¢ Reduction in incidence of complications â?¢ Reduction in hospital time â?¢ Laboratory markers (Laboratory Markers In Covid-19 Patients ) â?¢ Adverse events/effects Timepoint: ONE WEEK	—

Countries

India

Contacts

Public ContactDRSTHILLAIVANAN

DEPARTMENT OF INDIAN MEDICINE AND HOMEOPATHY

drthillai.mdsiddha@gmail.com8056040768

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026